|Table of Contents|

The efficacy of apatinib combined with intravenous chemotherapy in the treatment of advanced lung cancer associated with malignant pleural effusion

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 06
Page:
990-993
Research Field:
Publishing date:

Info

Title:
The efficacy of apatinib combined with intravenous chemotherapy in the treatment of advanced lung cancer associated with malignant pleural effusion
Author(s):
Yang Yanfeng; Pan Qin; Wang Chun
Oncology Department，Liyang People's Hospital，Jiangsu Liyang 213300,China.
Keywords:
apatinib; chemotherapy; malignant pleural effusion; advanced lung cancer
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2019.06.021
Abstract:
Objective:To investigate the effectiveness and safety of combined therapy of apatinib and intravenous chemotherapy in malignant pleural effusion (MPE) associated with advanced lung cancer.Methods:62 non-squamous and non-small cell lung cancer patients in accord with the inclusion criteria were retrospectively included.31 of them were treated with apatinib and intravenous chemotherapy (study group) and the other 31 patients were treated with intravenous chemotherapy only (control group).Efficacy and safety information were recorded and analyzed.Results:Most patients included in this study received first-line therapy and the disease control rate of study group was 90.3%，which was significantly higher than control group （77.4%）.Main adverse events were equal between two groups.Conclusion:Combined therapy of apatinib and chemotherapy could significantly improve the effective rate of MPE associated with advanced lung cancer.

References:

［1］Expert Consensus Group on Diagnosis and Treatment of Malignant Pleural Effusion in China.Expert consensus on diagnosis and treatment of malignant pleural effusions［J］.Chinese Journal of Internal Medicine,2014,53(3):252-256.［中国恶性胸腔积液诊断与治疗专家共识组.恶性胸腔积液诊断与治疗专家共识［J］.中华内科杂志,2014,53(3):252-256.］
[2] Shi H,Bai C.Interpretation of expert consensus on anti-angiogenic drugs for treatment of respiratory disease in advanced non-small cell lung cancer (2016 edition)［J］.Chinese Journal of Practical Internal Medicine,2017,37(02):127-131.［石荟，白冲.晚期非小细胞肺癌抗血管生成药物治疗中国呼吸领域专家共识解读(2016年版)［J］.中国实用内科杂志,2017，37(02):127-131.］
[3] Thomas R,Fysh ETH,Smith NA,et al.Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion［J］.JAMA,2017,318(19):1903.
[4] Roberts ME,Neville E,Berrisford RG,et al.Management of a malignant pleural effusion:British Thoracic Society Pleural Disease Guideline 2010［J］.Thorax,2010,65(Suppl 2):i32-i40.
[5] Bradshaw M,Mansfield A,Peikert T.The role of vascular endothelial growth factor in the pathogenesis,diagnosis and treatment of malignant pleural effusion［J］.Current Oncology Reports,2013,15(3):207-216.
[6] Masago K,Fujimoto D,Fujita S,et al.Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer［J］.Mol Clin Oncol,2015,3(2):415-419.
[7] Du N,Chen D,Li X,et al.The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion［J］.Indian Journal of Cancer,2014,51(7):82.
[8] Kim YM,Hwang S,Kim YM,et al.Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1［J］.J Biol Chem,2002,277(31):27872-27879.
[9] Biaoxue R,Xiguang C,Hua L,et al.Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions:A systematic evaluation and meta-analysis［J］.BMC Cancer,2016,16(1)：888-901.
[10] Maa HC,Chao TT,Wang CY,et al.VEGF-D as a marker in the aid of malignant metastatic pleural effusion diagnosis［J］.Appl Immunohistochem Mol Morphol,2015,23(3):209-214.
[11] Kim KL,Suh W.Apatinib,an inhibitor of vascular endothelial growth factor receptor 2,suppresses pathologic ocular neovascularization in mice［J］.Invest Ophthalmol Vis Sci,2017,58(9):3592-3599.
[12] Lee JE,Kim KL,Kim D,et al.Apatinib-loaded nanoparticles suppress vascular endothelial growth factor-induced angiogenesis and experimental corneal neovascularization［J］.2017,12:4813-4822.
[13] Jeong JH,Nguyen HK,Lee JE,et al.Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage［J］.Int J Nanomedicine,2016,11:3101-3109.
[14] Liu K,Ren T,Huang Y,et al.Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma［J］.Cell Death and Disease,2017,8(8):e3015.
[15] Zhou YY,Qin SK,Wang R,et al.Apatinib in the treatment of advanced gastric cancer with refractory cancer ascites in 4 cases［J］.Chinese Journal of Clinical Oncology,2016,21(05):476-478.［周阳阳，秦叔逵，汪蕊，等.阿帕替尼治疗晚期胃癌伴顽固性癌性腹水4例［J］.临床肿瘤学杂志,2016，21(05):476-478.］
[16] Zhu LY,Yu ZH,Xu CW,et al.Treatment of lung squamous cell carcinoma with apatinib in 1 case［J］.Chinese Journal of Clinical Oncology,2017,44(2):100.［朱礼阳，于忠和，许春伟，等.阿帕替尼治疗肺鳞癌1例［J］.中国肿瘤临床,2017,44(2):100.］

Memo

Memo:
-
Last Update: 1900-01-01